{"gene":"PPM1D","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":2002,"finding":"PPM1D (Wip1) dephosphorylates and inactivates p38 MAPK, creating a negative feedback loop on p53 activity. Retrovirus-mediated overexpression of PPM1D reduced p53 phosphorylation at Ser33 and Ser46 (p38 MAPK target sites), abrogated Ras-induced apoptosis, and partially rescued cells from cell-cycle arrest.","method":"Retroviral overexpression, phosphorylation analysis, apoptosis/cell-cycle assays, MEF transformation assay in nude mice","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (overexpression, phosphorylation assays, in vivo tumor formation), replicated across subsequent studies","pmids":["12021785"],"is_preprint":false},{"year":2005,"finding":"PPM1D binds Chk1 and dephosphorylates ATR-targeted phospho-Ser345, reducing Chk1 kinase activity. PPM1D also dephosphorylates p53 at phospho-Ser15. These dephosphorylations correlate with reduced intra-S and G2/M checkpoint activity after UV and ionizing radiation.","method":"Co-immunoprecipitation, in vitro phosphatase assay, checkpoint activity assays after UV/IR","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical dephosphorylation assay with functional checkpoint readout, replicated in subsequent studies","pmids":["15870257"],"is_preprint":false},{"year":2006,"finding":"Wip1 (PPM1D) dephosphorylates ATM at Ser1981, a site critical for ATM monomerization and activation, thereby resetting ATM phosphorylation as cells complete DNA repair. Overexpression of Wip1 reduces ATM-dependent signaling cascade activation after DNA damage; Wip1 deficiency results in constitutive ATM activation.","method":"In vitro phosphatase assay, overexpression and knockdown experiments, immunoblotting for ATM-S1981 phosphorylation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical dephosphorylation of ATM-S1981 demonstrated, replicated by multiple subsequent studies","pmids":["16949371"],"is_preprint":false},{"year":2004,"finding":"PPM1D interacts with the nuclear isoform of uracil DNA glycosylase UNG2 and suppresses base excision repair (BER). PPM1D dephosphorylates UNG2 at phosphothreonine 6, reducing UNG2 activity. Point mutations inactivating PPM1D phosphatase activity abrogate BER suppression.","method":"Co-immunoprecipitation, in vitro phosphatase assay, active-site mutagenesis, BER activity assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in vitro with active-site mutagenesis, direct substrate identification with functional BER readout","pmids":["15327777"],"is_preprint":false},{"year":2006,"finding":"Wip1 binds Chk2 and dephosphorylates phospho-Thr68 (the ATM-targeted activation site), thereby antagonizing Chk2 activation after ionizing irradiation. Wip1 overexpression suppresses the G2/M DNA damage checkpoint contribution of Chk2.","method":"Co-immunoprecipitation, in vitro phosphatase assay, G2/M checkpoint assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct biochemical dephosphorylation of Chk2-T68, functional checkpoint assay; independently confirmed by Yoda et al. same year","pmids":["16936775","16798742"],"is_preprint":false},{"year":2006,"finding":"Nuclear localization of both Chk2 and Wip1 is required for their association. The SQ/TQ domain of Chk2 (containing Thr68) and the N-terminal ~100 amino acids of Wip1 are necessary and sufficient for binding. Intrinsic kinase activity of Chk2 (but not phosphatase activity of Wip1) is required for their association when full-length proteins are used.","method":"Structure-function analysis with deletion and point mutants, co-immunoprecipitation, nuclear localization experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — systematic domain mapping with multiple mutants and Co-IP, functional rescue assays","pmids":["16798742"],"is_preprint":false},{"year":2007,"finding":"Recombinant Wip1 catalytic domain dephosphorylates phosphoserine and phosphothreonine specifically in the p(S/T)Q motif (ATM/ATR substrate motif). Acidic, hydrophobic, or aromatic residues flanking the p(S/T)Q enhance dephosphorylation; basic residues have negative influence. New putative substrates identified include HDM2, SMC1A, ATR, and Wip1 itself.","method":"In vitro phosphatase kinetics with peptide variants, site-directed mutagenesis, 3D molecular modeling","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — detailed kinetic analysis of recombinant enzyme with substrate peptide variants and mutagenesis","pmids":["17939684"],"is_preprint":false},{"year":2008,"finding":"PPM1D (Wip1) dephosphorylates Mdm2 at Ser395 (an ATM target site), stabilizing Mdm2, enhancing Mdm2-p53 binding, and promoting ubiquitination and degradation of p53. Wip1 thus facilitates Mdm2-mediated p53 degradation as part of a negative feedback loop.","method":"In vitro phosphatase assay, co-immunoprecipitation, ubiquitination assay, p53 stability measurements","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical dephosphorylation and functional p53 degradation assays, single lab","pmids":["18333294"],"is_preprint":false},{"year":2010,"finding":"Wip1 directly dephosphorylates γ-H2AX (phospho-H2AX) in vitro and in vivo. Ectopic Wip1 expression significantly reduces γ-H2AX levels after ionizing radiation and UV; forced premature dephosphorylation disrupts recruitment of DNA repair factors to damage sites and delays DNA damage repair.","method":"In vitro phosphatase assay, ectopic expression, immunofluorescence, DNA repair kinetics assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct in vitro dephosphorylation plus in vivo functional consequences on repair factor recruitment","pmids":["20460517"],"is_preprint":false},{"year":2010,"finding":"WIP1 overexpression inhibits nucleotide excision repair (NER) kinetics in a phosphatase-activity-dependent manner; phosphatase-dead WIP1 mutants fail to inhibit NER. XPA and XPC are identified as potential WIP1 dephosphorylation targets in the NER pathway.","method":"Overexpression and depletion experiments, CPD repair kinetics assay, in vitro phosphatase assay with XPA/XPC, phosphatase-dead mutant analysis","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — phosphatase-dead mutant controls establish catalytic requirement; in vitro substrate identification; Wip1 null mice corroborate findings","pmids":["20451471"],"is_preprint":false},{"year":2012,"finding":"Truncating gain-of-function mutations in exon 6 of PPM1D (carboxy-terminal to the phosphatase domain) result in enhanced suppression of p53 in response to ionizing radiation, without simple loss of function. These mosaic mutations encode hyperactive PPM1D isoforms.","method":"Next-generation sequencing, functional p53 suppression assay after IR in cells with exon 6 truncating variants","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional validation in cells, single lab but large case-control dataset","pmids":["23242139"],"is_preprint":false},{"year":2013,"finding":"Exon 6 truncating mutations in PPM1D result in C-terminally truncated Wip1 with gain-of-function activity that impairs the p53-dependent G1 checkpoint and affects the DNA damage response pathway.","method":"Identification and functional characterization of exon 6 mutations, cell cycle checkpoint assay, DDR pathway analysis","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional checkpoint assays with defined mutants, single lab","pmids":["23649806"],"is_preprint":false},{"year":2013,"finding":"Wip1 is required for epigenetic remodeling of heterochromatin through regulation of BRCA1 interaction with HP1, recruitment of DNA methyltransferases, and subsequent DNA methylation. ATM attenuation reverses heterochromatin methylation, placing Wip1 upstream of ATM in heterochromatin silencing.","method":"Chromatin immunoprecipitation, DNA methylation assays, co-immunoprecipitation (BRCA1-HP1), genetic epistasis with ATM","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple ChIP and co-IP approaches, genetic epistasis, single lab","pmids":["24135283"],"is_preprint":false},{"year":2014,"finding":"PPM1D exon 6 truncating mutations in brainstem gliomas enhance PPM1D's ability to suppress CHK2 activation and attenuate p53 activation in vitro, establishing these as gain-of-function somatic driver mutations.","method":"Exome sequencing, functional in vitro assays for CHK2 suppression and p53 activation","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional validation of identified mutations, single study","pmids":["24880341"],"is_preprint":false},{"year":2014,"finding":"Allosteric small-molecule inhibitors of Wip1 bind a 'flap' subdomain near the catalytic site that is structurally divergent from other PP2C family members, conferring selectivity. GSK2830371 binding to this site increases phosphorylation of Wip1 substrates and inhibits growth of hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53.","method":"Structure-activity relationship, biochemical binding assay, pharmacodynamic studies, xenograft tumor model","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — structural basis of inhibition defined, multiple orthogonal biochemical and cellular methods, in vivo validation","pmids":["24390428"],"is_preprint":false},{"year":2014,"finding":"Phosphoglycerate mutase 1 (PGAM1) binds WIP1 in the cytoplasm, preventing its nuclear translocation and subsequent dephosphorylation of the ATM signaling pathway, thereby regulating DNA damage response efficiency.","method":"Co-immunoprecipitation (cytoplasmic fractionation), PGAM1 knockdown, γ-H2AX foci assay, kinase-dead mutant rescue","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with subcellular fractionation, functional DDR readout, non-enzymatic PGAM1 mutant rescue establishes mechanism","pmids":["32294440"],"is_preprint":false},{"year":2015,"finding":"PPM1D interacts with and dephosphorylates Ulk1 at Ser637 in a p53-dependent manner after genotoxic stress, triggering Ulk1 puncta formation and inducing autophagy. Genetic ablation of PPM1D reduces Ulk1 Ser637 dephosphorylation, inhibits autophagy, and accelerates apoptosis induced by X-ray irradiation by preventing autophagic degradation of proapoptotic Noxa.","method":"Co-immunoprecipitation, in vitro phosphatase assay, Ulk1 puncta imaging, genetic KO, autophagy flux assay, apoptosis assay","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct biochemical interaction and dephosphorylation established, genetic KO corroborates physiological role with specific molecular readouts","pmids":["27670885"],"is_preprint":false},{"year":2015,"finding":"PPM1D dephosphorylates RBM38 at serine 195, modulating p53 mRNA translation. RBM38 directly binds PPM1D 3'-UTR and promotes PPM1D expression; PPM1D dephosphorylation of RBM38 reduces p53 mRNA translation and p53-dependent growth suppression.","method":"Co-immunoprecipitation, in vitro dephosphorylation assay, luciferase reporter (3'-UTR), RNA-binding assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — direct biochemical dephosphorylation and RNA-binding assays demonstrated, single lab","pmids":["25823026"],"is_preprint":false},{"year":2015,"finding":"Wip1 deficiency in HSCs leads to sustained p53 activation, impaired repopulating activity, and aging-like phenotypes. Deletion of p53 (but not p21) completely rescues the multilineage repopulation defect of Wip1-deficient HSCs, defining a Wip1-p53 axis in HSC differentiation. Separately, HSC pool expansion in Wip1-/- mice is mediated by mTORC1-dependent proliferation, distinct from the p53-dependent differentiation defect.","method":"Conditional knockout, bone marrow transplantation competition assay, genetic epistasis (p53 deletion rescue), flow cytometry, mTORC1 pathway analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with rescue experiment separates two distinct pathways; multiple orthogonal in vivo methods","pmids":["25879755"],"is_preprint":false},{"year":2018,"finding":"PPM1D truncating mutations (exon 6) encode a protein with elevated expression and activity due to loss of a C-terminal degradation domain. Global phosphoproteomic profiling in PPM1D-mutant cells reveals altered phosphorylation of DNA damage response targets. PPM1D-mutant cells show abrogated DDR, altered cell cycle progression, decreased apoptosis, and reduced mitochondrial priming in the presence of chemotherapy.","method":"Phosphoproteomics (mass spectrometry), CRISPR mutational profiling, cell cycle and apoptosis assays, mitochondrial priming assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — global phosphoproteomics plus multiple orthogonal functional assays, CRISPR validation","pmids":["29954749"],"is_preprint":false},{"year":2019,"finding":"WIP1 promotes homologous recombination (HR) DNA repair. WIP1 interacts with BRCA1 and dephosphorylates it; WIP1 activity is needed for correct dynamics of BRCA1 recruitment to chromatin flanking DNA lesions. WIP1 also dephosphorylates 53BP1 at Threonine 543, previously implicated in mediating interaction with RIF1. Loss/inhibition of WIP1 delayed disappearance of IR-induced 53BP1 foci in S/G2 cells and increased sensitivity to PARP inhibitor olaparib.","method":"Co-immunoprecipitation, in vitro dephosphorylation assay, immunofluorescence (53BP1/BRCA1 foci), WIP1 inhibitor treatment, olaparib sensitivity assay","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding and biochemical dephosphorylation of BRCA1 and 53BP1 demonstrated, functional HR readout, single lab","pmids":["31619012"],"is_preprint":false},{"year":2019,"finding":"Mutant PPM1D drives CpG island hypermethylation genome-wide and promotes epigenetic silencing of NAPRT (a NAD biosynthesis gene), creating a synthetic lethal interaction with NAMPT inhibitors.","method":"Isogenic cell lines, genome-wide methylation profiling, NAMPT inhibitor sensitivity assay in vitro and in vivo","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isogenic models with mechanistic methylation data and in vivo validation, single lab","pmids":["31439867"],"is_preprint":false},{"year":2020,"finding":"Wip1 selectively binds and dephosphorylates Smad4 at Thr277 (a key MAPK phosphorylation site in the linker region), regulating Smad4 nuclear accumulation and half-life. This inhibits TGF-β/BMP signaling; in Xenopus embryos, Wip1 limits mesoderm formation by inhibiting TGF-β/BMP signals.","method":"Co-immunoprecipitation, in vitro phosphatase assay, nuclear fractionation, Xenopus embryo gain/loss-of-function, cell migration/invasion assay","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct biochemical binding and dephosphorylation, functional in vivo Xenopus model, subcellular localization consequences defined","pmids":["32103600"],"is_preprint":false},{"year":2016,"finding":"PPM1D regulates nucleolar formation by controlling phosphorylation of nucleophosmin (NPM). PPM1D overexpression induces increased nucleolar number independently of p53 status. PPM1D acts as an upstream regulator in a PPM1D-CDC25C-CDK1-PLK1 signaling pathway that controls sequential NPM phosphorylation required for nucleolar formation.","method":"Overexpression, knockdown, immunofluorescence (nucleolar counting), phospho-NPM analysis, pathway epistasis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional pathway placement with mechanistic cascade delineation, single lab, p53-independence established","pmids":["27619510"],"is_preprint":false},{"year":2022,"finding":"GSK2830371 binds an allosteric site of PPM1D (the flap domain). Hydrogen-deuterium exchange mass spectrometry and analytical ultracentrifugation reveal PPM1D exists in equilibrium between two conformations defined by flap domain movement; GSK2830371 shifts the equilibrium to the inactive (flap-closed) form. C-terminal truncating mutations proximal to residue 400 destabilize the protein via loss of a stabilizing N- and C-terminal interaction.","method":"HDX-MS, sedimentation velocity analytical ultracentrifugation, computational modeling, biochemical binding assays, functional genetic studies","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple structural/biophysical methods (HDX-MS, AUC) plus biochemical and functional genetic validation in a single rigorous study","pmids":["35773251"],"is_preprint":false},{"year":2022,"finding":"PPM1D inhibition induces phosphorylation of eIF2α and ATF4 accumulation, linking PPM1D to the integrated stress response (ISR). PPM1D inhibition depletes heme and induces HRI-dependent eIF2α phosphorylation. Dual inhibition of PPM1D and MDM2 synergistically induces apoptosis via amplification of p53 transcriptional program through the eIF2α-ATF4 pathway.","method":"PPM1D inhibitor treatment, eIF2α phosphorylation assay, ATF4 reporter, HRI pathway analysis, RNA-seq, in vivo tumor growth assay","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway dissection with pharmacological and genetic tools, in vivo validation, single lab","pmids":["36456590"],"is_preprint":false},{"year":2008,"finding":"A conserved p53 response element in the 5' UTR of the PPM1D gene is required for p53-dependent transcriptional induction after genotoxic stress. CREB binding to a CRE element in the promoter regulates basal PPM1D expression. After UV/IR exposure, increased PPM1D protein levels can occur without increased mRNA, indicating post-transcriptional regulation.","method":"Transient transfection, chromatin immunoprecipitation, promoter reporter assay, mRNA/protein comparison after DNA damage","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assays establish transcriptional mechanism, single lab, multiple methods","pmids":["19015127"],"is_preprint":false},{"year":2012,"finding":"Wip1 deficiency prevents fat accumulation and atherosclerosis in mice. During atherosclerosis, Wip1 deletion suppresses macrophage conversion to foam cells by acting via a non-canonical ATM-mTOR signaling pathway and selective autophagy to regulate cholesterol efflux, in a p53-independent manner.","method":"Wip1 knockout mouse model, atherosclerosis model, macrophage foam cell assay, autophagy and cholesterol efflux assays, genetic epistasis with ATM/mTOR","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with mechanistic dissection of ATM-mTOR-autophagy pathway, p53-independence established, single lab","pmids":["22768840"],"is_preprint":false},{"year":2014,"finding":"WIP1 promotes medulloblastoma cell growth and invasion through regulation of CXCR4 cell surface localization via suppression of GRK5 expression. GRK5 promotes Ser339 phosphorylation of CXCR4 and inhibits cell surface CXCR4; WIP1 knockdown reduces GRK5-dependent CXCR4 phosphorylation, decreasing surface CXCR4 and invasion.","method":"Stable knockdown/overexpression, xenograft mouse model, cell surface CXCR4 assay, GRK5 manipulation, invasion assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo mechanistic pathway delineation, multiple molecular manipulations, single lab","pmids":["24632620"],"is_preprint":false},{"year":2014,"finding":"WIP1 regulates adult neurogenesis by controlling DKK3-dependent inhibition of WNT signaling. WIP1 is expressed in neural stem/progenitor cells (NPCs) of the mouse SVZ; WIP1 suppresses expression of the WNT pathway inhibitor DKK3. DKK3 inhibits neuroblast formation by suppressing WNT signaling, and Wip1-dependent control of DKK3 promotes neuronal differentiation.","method":"Transgenic mice with enhanced WIP1 expression, Dkk3 deletion, pharmacological WNT activation, SVZ reporter strain, olfactory behavioral testing","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (Wip1 → DKK3 → WNT) established with multiple mouse models and functional behavioral readout","pmids":["24911145"],"is_preprint":false},{"year":2009,"finding":"Loss of Wip1 sensitizes mouse embryonic fibroblasts to stress-induced apoptosis via activation of both p38-ATF2 and JNK-c-Jun signaling. Wip1 negatively regulates MKK4-JNK-c-Jun signaling during stress-induced apoptosis, representing a dual role in regulating both p38/p53-dependent and JNK-dependent apoptotic pathways.","method":"Wip1 knockout MEFs, stress-induced apoptosis assays, kinase activity measurements (p38, JNK), phospho-ATF2/c-Jun analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with pathway dissection, single lab, multiple kinase pathway readouts","pmids":["19395378"],"is_preprint":false},{"year":2021,"finding":"p21WAF1/CIP1 promotes the interaction between p53 and Wip1 by forming a trimeric complex (p53-p21-Wip1), facilitating Wip1-mediated dephosphorylation of p53-S15 and subsequent Mdm2-mediated p53 degradation. A p21 deletion mutant unable to bind p53 cannot facilitate p53-Wip1 interaction.","method":"Co-immunoprecipitation, deletion mutant analysis, p53 stability assay, phospho-S15 immunoblotting","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with domain mapping establishes trimeric complex, functional phosphorylation readout, single lab","pmids":["33503543"],"is_preprint":false},{"year":2017,"finding":"Wip1-deficient macrophages show enhanced migration mediated by Rac1-GTPase and PI3K/AKT signaling pathways. Enhanced phagocytic ability of Wip1-/- macrophages is linked to CD36 plasma membrane recruitment regulated by AMPK activity.","method":"Wip1 knockout macrophage migration and phagocytosis assays, Rac1-GTPase activity measurement, PI3K/AKT pathway analysis, AMPK activity, CD36 membrane recruitment assay","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with mechanistic pathway dissection, multiple signaling pathway measurements, single lab","pmids":["28822916"],"is_preprint":false},{"year":2014,"finding":"Akt stabilizes PPM1D protein by inhibiting CDDP-induced proteasomal degradation. In chemoresistant gynecological cancer cells, CDDP induces PPM1D nuclear localization while sensitive cells show nuclear exclusion. Active Akt overexpression in sensitive cells stabilizes PPM1D and prevents degradation.","method":"Nuclear/cytoplasmic fractionation, proteasome inhibitor assay, Akt overexpression/inhibition, PPM1D stability measurements","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular localization determined by fractionation with functional consequence, Akt regulation of PPM1D stability established, single lab","pmids":["25154814"],"is_preprint":false}],"current_model":"PPM1D (Wip1) is a p53-inducible PP2C-family serine/threonine phosphatase that dephosphorylates and inactivates multiple ATM/ATR pathway substrates—including ATM-pS1981, Chk1-pS345, Chk2-pT68, p53-pS15, γ-H2AX, Mdm2-pS395, Ulk1-pS637, Smad4-pT277, BRCA1, 53BP1-pT543, UNG2-pT6, RBM38-pS195, XPA, and XPC—thereby acting as a homeostatic phosphatase that attenuates the DNA damage response, cell cycle checkpoints, base excision repair, nucleotide excision repair, and homologous recombination after DNA repair is complete; its oncogenic amplification or C-terminal truncating gain-of-function mutations increase protein stability and phosphatase activity, broadly suppressing tumor suppressor pathways including p53, p38 MAPK, and ATM, while allosteric inhibitors such as GSK2830371 lock the flap subdomain in an inactive conformation to restore these pathways in cancer cells."},"narrative":{"mechanistic_narrative":"PPM1D (Wip1) is a p53-inducible PP2C-family serine/threonine phosphatase that acts as a homeostatic brake on the DNA damage response, dephosphorylating ATM/ATR pathway substrates within the p(S/T)Q motif to reset checkpoint signaling once repair is complete [PMID:15870257, PMID:17939684]. Its catalytic domain recognizes phospho-Ser/Thr in p(S/T)Q sequences, with flanking acidic/hydrophobic residues enhancing turnover [PMID:17939684], and it directly inactivates the core checkpoint machinery: ATM at Ser1981 [PMID:16949371], Chk1 at Ser345 [PMID:15870257], Chk2 at Thr68 [PMID:16936775, PMID:16798742], p53 at Ser15 [PMID:15870257], and γ-H2AX [PMID:20460517]. PPM1D reinforces a negative feedback loop on p53 both by dephosphorylating Mdm2-Ser395 to promote Mdm2-mediated p53 degradation [PMID:18333294]—a process facilitated by a p53-p21-Wip1 trimeric complex [PMID:33503543]—and by inactivating p38 MAPK to attenuate p53 phosphorylation and apoptosis [PMID:12021785]. Its own induction is driven by a p53 response element in the 5'UTR after genotoxic stress [PMID:19015127]. Beyond canonical checkpoint control, PPM1D suppresses multiple repair pathways by dephosphorylating UNG2-Thr6 (base excision repair) [PMID:15327777], XPA/XPC (nucleotide excision repair) [PMID:20451471], and BRCA1 and 53BP1-Thr543 (homologous recombination) [PMID:31619012], and it extends to autophagy via Ulk1-Ser637 [PMID:27670885], TGF-β/BMP signaling via Smad4-Thr277 [PMID:32103600], and p53 mRNA translation via RBM38-Ser195 [PMID:25823026]. Oncogenic activation occurs through amplification or C-terminal exon 6 truncating gain-of-function mutations that remove a degradation domain, elevating protein stability and activity and broadly suppressing p53 and DDR signaling [PMID:23242139, PMID:23649806, PMID:29954749, PMID:35773251]. The allosteric inhibitor GSK2830371 binds a divergent 'flap' subdomain and shifts PPM1D toward an inactive flap-closed conformation, restoring substrate phosphorylation and selectively impairing growth of Wip1-amplified, TP53-wild-type tumors [PMID:24390428, PMID:35773251]. PPM1D also has p53-independent physiological roles in hematopoietic stem cell homeostasis, neurogenesis, macrophage function, and atherosclerosis [PMID:25879755, PMID:22768840, PMID:24911145].","teleology":[{"year":2002,"claim":"Established PPM1D as a phosphatase that closes a negative feedback loop on stress signaling, dephosphorylating p38 MAPK to limit p53 activation and apoptosis—defining its oncogenic potential.","evidence":"Retroviral overexpression with phosphorylation, apoptosis, and in vivo MEF transformation assays","pmids":["12021785"],"confidence":"High","gaps":["Did not identify direct DDR kinase substrates","p38 dephosphorylation may be indirect"]},{"year":2004,"claim":"Extended PPM1D's reach beyond checkpoints to DNA repair itself by showing direct dephosphorylation of UNG2-Thr6 suppresses base excision repair.","evidence":"Co-IP, in vitro phosphatase assay with active-site mutants, BER activity readout","pmids":["15327777"],"confidence":"High","gaps":["In vivo significance of BER suppression not established","Did not place UNG2 regulation in broader repair context"]},{"year":2005,"claim":"Identified PPM1D as a direct antagonist of the ATR-Chk1 and p53 checkpoint arms, dephosphorylating Chk1-Ser345 and p53-Ser15 to dampen intra-S and G2/M checkpoints.","evidence":"Co-IP, in vitro phosphatase assays, checkpoint readouts after UV/IR","pmids":["15870257"],"confidence":"High","gaps":["Did not address upstream ATM/ATR directly","Relative contribution of each substrate to checkpoint output unquantified"]},{"year":2006,"claim":"Placed PPM1D at the apex of DDR reset by demonstrating it dephosphorylates ATM-Ser1981 and Chk2-Thr68, defining nuclear localization and N-terminal/SQ-TQ domain requirements for substrate binding.","evidence":"In vitro phosphatase assays, knockdown/overexpression, structure-function domain mapping","pmids":["16949371","16936775","16798742"],"confidence":"High","gaps":["Kinetics of ATM reset relative to repair completion not resolved","Whether ATM dephosphorylation is direct or scaffold-dependent in cells"]},{"year":2007,"claim":"Defined the biochemical substrate logic of PPM1D as a p(S/T)Q-directed phosphatase, rationalizing its selectivity for ATM/ATR substrates and predicting new targets.","evidence":"In vitro phosphatase kinetics with peptide variants, mutagenesis, molecular modeling","pmids":["17939684"],"confidence":"High","gaps":["Predicted substrates (HDM2, SMC1A, ATR) not all validated in cells","No experimental structure of substrate-bound enzyme"]},{"year":2008,"claim":"Connected PPM1D to p53 turnover and its own transcriptional induction, showing Mdm2-Ser395 dephosphorylation promotes p53 degradation and a p53 response element drives PPM1D expression.","evidence":"In vitro phosphatase, ubiquitination, p53 stability assays; ChIP and promoter reporters","pmids":["18333294","19015127"],"confidence":"Medium","gaps":["Post-transcriptional induction mechanism after UV/IR undefined","Mdm2 stabilization mechanism single-lab"]},{"year":2010,"claim":"Showed PPM1D directly dephosphorylates γ-H2AX and suppresses nucleotide excision repair, establishing premature dephosphorylation as a means of disrupting repair-factor recruitment.","evidence":"In vitro phosphatase assays, ectopic expression, immunofluorescence, repair kinetics with phosphatase-dead controls","pmids":["20460517","20451471"],"confidence":"High","gaps":["XPA/XPC identified as potential rather than confirmed in vivo substrates","Timing of γ-H2AX reset versus repair completion not fully resolved"]},{"year":2012,"claim":"Reframed PPM1D mutation from loss to gain of function, showing exon 6 truncating mutations encode hyperactive isoforms that enhance p53 suppression after irradiation.","evidence":"NGS plus functional p53 suppression assays in cells carrying exon 6 variants","pmids":["23242139"],"confidence":"Medium","gaps":["Molecular basis of hyperactivity not yet defined at this stage","Clonal context of mosaic mutations unclear"]},{"year":2013,"claim":"Defined exon 6 truncating mutations as G1-checkpoint-impairing gain-of-function alleles and linked PPM1D to BRCA1/HP1-dependent heterochromatin silencing upstream of ATM.","evidence":"Mutant functional checkpoint assays; ChIP, DNA methylation, co-IP, and ATM epistasis","pmids":["23649806","24135283"],"confidence":"Medium","gaps":["Heterochromatin role single-lab and mechanism of DNMT recruitment incomplete","Direct vs indirect BRCA1 effect on methylation unresolved"]},{"year":2014,"claim":"Identified the druggable allosteric flap subdomain and validated PPM1D as a selective therapeutic target, while expanding its oncogenic roles to brainstem glioma drivers, CXCR4/GRK5 invasion, and WNT-dependent neurogenesis.","evidence":"SAR and GSK2830371 binding/PD/xenograft studies; exome sequencing with functional CHK2/p53 assays; knockdown/xenograft invasion and neurogenesis mouse models","pmids":["24390428","24880341","24632620","24911145"],"confidence":"High","gaps":["Detailed conformational mechanism of inhibition not yet defined at this stage","Tissue specificity of CXCR4 and WNT roles unclear"]},{"year":2015,"claim":"Broadened PPM1D's substrate repertoire to autophagy (Ulk1-Ser637), p53 mRNA translation (RBM38-Ser195), HR repair via BRCA1, and revealed a p53-dependent HSC differentiation axis distinct from mTORC1-driven HSC expansion.","evidence":"Co-IP, in vitro dephosphorylation, autophagy flux/apoptosis assays, RNA-binding/luciferase, conditional KO with p53-deletion rescue and transplantation","pmids":["27670885","25823026","25879755"],"confidence":"High","gaps":["RBM38 feedback loop single-lab","Tissue-specific balance of these substrates unquantified"]},{"year":2016,"claim":"Revealed a p53-independent role in nucleolar biogenesis through a PPM1D-CDC25C-CDK1-PLK1 cascade controlling NPM phosphorylation.","evidence":"Overexpression/knockdown, nucleolar counting, phospho-NPM analysis, pathway epistasis","pmids":["27619510"],"confidence":"Medium","gaps":["Direct vs indirect control of NPM phosphorylation unclear","Single-lab pathway placement"]},{"year":2017,"claim":"Defined p53-independent immune functions: Wip1 loss enhances macrophage migration via Rac1-PI3K/AKT and phagocytosis via AMPK-driven CD36 recruitment.","evidence":"Wip1 KO macrophage migration/phagocytosis assays with Rac1, PI3K/AKT, AMPK pathway readouts","pmids":["28822916"],"confidence":"Medium","gaps":["Direct substrates in these pathways not identified","Single-lab"]},{"year":2018,"claim":"Provided the mechanistic basis for gain-of-function mutations—loss of a C-terminal degradation domain elevating PPM1D abundance and activity—and globally mapped the resulting DDR phosphoproteome changes.","evidence":"Phosphoproteomics, CRISPR mutational profiling, cell cycle/apoptosis and mitochondrial priming assays","pmids":["29954749"],"confidence":"High","gaps":["Which phosphoproteomic changes are direct substrates unresolved","Chemoresistance mechanism only partially mapped"]},{"year":2019,"claim":"Established PPM1D as a regulator of HR repair through BRCA1 and 53BP1-Thr543 dephosphorylation and revealed a therapeutically exploitable epigenetic vulnerability (NAPRT silencing, NAMPT synthetic lethality) in mutant cells.","evidence":"Co-IP, in vitro dephosphorylation, 53BP1/BRCA1 foci imaging, olaparib sensitivity; isogenic lines with genome-wide methylation and NAMPT inhibitor assays","pmids":["31619012","31439867"],"confidence":"Medium","gaps":["HR role single-lab","Mechanism linking mutant PPM1D to CpG hypermethylation incomplete"]},{"year":2020,"claim":"Extended PPM1D into developmental signaling control by showing Smad4-Thr277 dephosphorylation limits TGF-β/BMP signaling and mesoderm formation, and identified PGAM1 as a cytoplasmic sequestering regulator of PPM1D nuclear import.","evidence":"Co-IP, in vitro phosphatase, nuclear fractionation, Xenopus gain/loss-of-function; cytoplasmic co-IP with non-enzymatic PGAM1 mutant rescue","pmids":["32103600","32294440"],"confidence":"Medium","gaps":["Physiological contexts of Smad4 regulation in mammals unclear","Signals controlling PGAM1-PPM1D binding undefined"]},{"year":2022,"claim":"Defined the conformational mechanism of allosteric inhibition—GSK2830371 locks a flap-domain equilibrium in the inactive state—and linked PPM1D inhibition to the integrated stress response, enabling MDM2-combination apoptosis.","evidence":"HDX-MS, analytical ultracentrifugation, modeling, biochemistry; eIF2α/ATF4/HRI pathway analysis, RNA-seq, in vivo tumor assays","pmids":["35773251","36456590"],"confidence":"High","gaps":["No high-resolution crystal/cryo-EM structure of inhibitor-bound PPM1D","ISR linkage to heme depletion mechanism single-lab"]},{"year":null,"claim":"How PPM1D's broad substrate set is spatiotemporally prioritized—and which downstream effects of gain-of-function mutants are direct catalytic events versus secondary consequences—remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experimental structure of substrate- or full-length protein","Substrate prioritization across DDR, autophagy, translation, and developmental signaling not integrated","Direct vs indirect basis of mutant-driven epigenetic and metabolic phenotypes"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,3,4,6,7,8,16,17,20,22]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,6,9]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,15,33]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[23]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[2,3,8,9,20]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,4,11,23]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,2,25,30]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[16,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,22,28,29,32]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[12,21]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,16,30]}],"complexes":["p53-p21-Wip1 trimeric complex"],"partners":["TP53","CHEK1","CHEK2","ATM","MDM2","BRCA1","UNG","PGAM1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15297","full_name":"Protein phosphatase 1D","aliases":["Protein phosphatase 2C isoform delta","PP2C-delta","Protein phosphatase magnesium-dependent 1 delta","p53-induced protein phosphatase 1"],"length_aa":605,"mass_kda":66.7,"function":"Involved in the negative regulation of p53 expression (PubMed:23242139). Required for the relief of p53-dependent checkpoint mediated cell cycle arrest. Binds to and dephosphorylates 'Ser-15' of TP53 and 'Ser-345' of CHEK1 which contributes to the functional inactivation of these proteins (PubMed:15870257, PubMed:16311512). Mediates MAPK14 dephosphorylation and inactivation (PubMed:21283629). Is also an important regulator of global heterochromatin silencing and critical in maintaining genome integrity (By similarity)","subcellular_location":"Nucleus; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/O15297/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PPM1D","classification":"Not Classified","n_dependent_lines":212,"n_total_lines":1208,"dependency_fraction":0.17549668874172186},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PPM1D","total_profiled":1310},"omim":[{"mim_id":"619092","title":"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, IMPAIRED LANGUAGE, EPILEPSY, AND GAIT ABNORMALITIES; NEDMILEG","url":"https://www.omim.org/entry/619092"},{"mim_id":"619091","title":"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, IMPAIRED LANGUAGE, AND GAIT ABNORMALITIES; NEDMILG","url":"https://www.omim.org/entry/619091"},{"mim_id":"617450","title":"JANSEN-DE VRIES SYNDROME; JDVS","url":"https://www.omim.org/entry/617450"},{"mim_id":"605324","title":"AMYLOID BETA PRECURSOR PROTEIN-BINDING PROTEIN 2; APPBP2","url":"https://www.omim.org/entry/605324"},{"mim_id":"605100","title":"PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1D; PPM1D","url":"https://www.omim.org/entry/605100"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PPM1D"},"hgnc":{"alias_symbol":["Wip1","PP2C-DELTA"],"prev_symbol":[]},"alphafold":{"accession":"O15297","domains":[{"cath_id":"3.60.40.10","chopping":"7-34_95-218_272-395","consensus_level":"medium","plddt":91.7176,"start":7,"end":395}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15297","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15297-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15297-F1-predicted_aligned_error_v6.png","plddt_mean":67.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PPM1D","jax_strain_url":"https://www.jax.org/strain/search?query=PPM1D"},"sequence":{"accession":"O15297","fasta_url":"https://rest.uniprot.org/uniprotkb/O15297.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15297/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15297"}},"corpus_meta":[{"pmid":"12021785","id":"PMC_12021785","title":"Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12021785","citation_count":372,"is_preprint":false},{"pmid":"30388424","id":"PMC_30388424","title":"PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.","date":"2018","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/30388424","citation_count":344,"is_preprint":false},{"pmid":"15870257","id":"PMC_15870257","title":"PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15870257","citation_count":329,"is_preprint":false},{"pmid":"16949371","id":"PMC_16949371","title":"Wip1 phosphatase modulates ATM-dependent signaling pathways.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16949371","citation_count":291,"is_preprint":false},{"pmid":"18265945","id":"PMC_18265945","title":"The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.","date":"2008","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18265945","citation_count":208,"is_preprint":false},{"pmid":"12702577","id":"PMC_12702577","title":"PPM1D is a potential target for 17q gain in neuroblastoma.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12702577","citation_count":203,"is_preprint":false},{"pmid":"23242139","id":"PMC_23242139","title":"Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23242139","citation_count":202,"is_preprint":false},{"pmid":"29954749","id":"PMC_29954749","title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29954749","citation_count":195,"is_preprint":false},{"pmid":"24390428","id":"PMC_24390428","title":"Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction.","date":"2014","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/24390428","citation_count":173,"is_preprint":false},{"pmid":"24880341","id":"PMC_24880341","title":"Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.","date":"2014","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24880341","citation_count":144,"is_preprint":false},{"pmid":"19293255","id":"PMC_19293255","title":"PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19293255","citation_count":141,"is_preprint":false},{"pmid":"23649806","id":"PMC_23649806","title":"Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.","date":"2013","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23649806","citation_count":140,"is_preprint":false},{"pmid":"20460517","id":"PMC_20460517","title":"Wip1 directly dephosphorylates gamma-H2AX and attenuates the DNA damage response.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20460517","citation_count":129,"is_preprint":false},{"pmid":"20668064","id":"PMC_20668064","title":"Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20668064","citation_count":128,"is_preprint":false},{"pmid":"22768840","id":"PMC_22768840","title":"Wip1-dependent regulation of autophagy, obesity, and atherosclerosis.","date":"2012","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22768840","citation_count":120,"is_preprint":false},{"pmid":"19879149","id":"PMC_19879149","title":"WIP1 phosphatase at the crossroads of cancer and aging.","date":"2009","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19879149","citation_count":112,"is_preprint":false},{"pmid":"17932621","id":"PMC_17932621","title":"Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D.","date":"2007","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17932621","citation_count":111,"is_preprint":false},{"pmid":"15327777","id":"PMC_15327777","title":"The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair.","date":"2004","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/15327777","citation_count":108,"is_preprint":false},{"pmid":"16936775","id":"PMC_16936775","title":"The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16936775","citation_count":94,"is_preprint":false},{"pmid":"20940041","id":"PMC_20940041","title":"Control of p53 and NF-κB signaling by WIP1 and MIF: role in cellular senescence and organismal aging.","date":"2010","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/20940041","citation_count":90,"is_preprint":false},{"pmid":"35585670","id":"PMC_35585670","title":"Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35585670","citation_count":84,"is_preprint":false},{"pmid":"22201816","id":"PMC_22201816","title":"Regulation of the Wip1 phosphatase and its effects on the stress response.","date":"2012","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/22201816","citation_count":82,"is_preprint":false},{"pmid":"16254685","id":"PMC_16254685","title":"The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.","date":"2005","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/16254685","citation_count":82,"is_preprint":false},{"pmid":"17700519","id":"PMC_17700519","title":"A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17700519","citation_count":79,"is_preprint":false},{"pmid":"27670885","id":"PMC_27670885","title":"Identification of PPM1D as an essential Ulk1 phosphatase for genotoxic stress-induced autophagy.","date":"2016","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/27670885","citation_count":76,"is_preprint":false},{"pmid":"16652371","id":"PMC_16652371","title":"Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.","date":"2006","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16652371","citation_count":67,"is_preprint":false},{"pmid":"24911145","id":"PMC_24911145","title":"Phosphatase WIP1 regulates adult neurogenesis and WNT signaling during aging.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24911145","citation_count":67,"is_preprint":false},{"pmid":"24395919","id":"PMC_24395919","title":"Phosphatase Wip1 negatively regulates neutrophil migration and inflammation.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24395919","citation_count":66,"is_preprint":false},{"pmid":"24135283","id":"PMC_24135283","title":"Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation.","date":"2013","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/24135283","citation_count":61,"is_preprint":false},{"pmid":"31439867","id":"PMC_31439867","title":"PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31439867","citation_count":58,"is_preprint":false},{"pmid":"21927021","id":"PMC_21927021","title":"The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21927021","citation_count":58,"is_preprint":false},{"pmid":"17939684","id":"PMC_17939684","title":"The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases.","date":"2007","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17939684","citation_count":56,"is_preprint":false},{"pmid":"25658463","id":"PMC_25658463","title":"WIP1 phosphatase as a potential therapeutic target in neuroblastoma.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25658463","citation_count":55,"is_preprint":false},{"pmid":"20543821","id":"PMC_20543821","title":"PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.","date":"2010","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/20543821","citation_count":54,"is_preprint":false},{"pmid":"25879755","id":"PMC_25879755","title":"Wip1 deficiency impairs haematopoietic stem cell function via p53 and mTORC1 pathways.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25879755","citation_count":54,"is_preprint":false},{"pmid":"16897432","id":"PMC_16897432","title":"Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers.","date":"2006","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/16897432","citation_count":52,"is_preprint":false},{"pmid":"17685927","id":"PMC_17685927","title":"Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.","date":"2007","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/17685927","citation_count":51,"is_preprint":false},{"pmid":"19015127","id":"PMC_19015127","title":"Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19015127","citation_count":50,"is_preprint":false},{"pmid":"28439615","id":"PMC_28439615","title":"WIP1 phosphatase as pharmacological target in cancer therapy.","date":"2017","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/28439615","citation_count":49,"is_preprint":false},{"pmid":"28144241","id":"PMC_28144241","title":"Phosphatase Wip1 in Immunity: An Overview and Update.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28144241","citation_count":49,"is_preprint":false},{"pmid":"32296033","id":"PMC_32296033","title":"WIP1 promotes cancer stem cell properties by inhibiting p38 MAPK in NSCLC.","date":"2020","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32296033","citation_count":47,"is_preprint":false},{"pmid":"16798742","id":"PMC_16798742","title":"Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16798742","citation_count":46,"is_preprint":false},{"pmid":"26883196","id":"PMC_26883196","title":"Wip1 phosphatase: between p53 and MAPK kinases pathways.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26883196","citation_count":45,"is_preprint":false},{"pmid":"22340722","id":"PMC_22340722","title":"Wip1-dependent signaling pathways in health and diseases.","date":"2012","source":"Progress in molecular biology and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/22340722","citation_count":45,"is_preprint":false},{"pmid":"25742468","id":"PMC_25742468","title":"Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.","date":"2015","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25742468","citation_count":45,"is_preprint":false},{"pmid":"35105861","id":"PMC_35105861","title":"PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35105861","citation_count":43,"is_preprint":false},{"pmid":"24632620","id":"PMC_24632620","title":"The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24632620","citation_count":43,"is_preprint":false},{"pmid":"20451471","id":"PMC_20451471","title":"The oncogenic phosphatase WIP1 negatively regulates nucleotide excision repair.","date":"2010","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/20451471","citation_count":43,"is_preprint":false},{"pmid":"32006900","id":"PMC_32006900","title":"The role of PPM1D in cancer and advances in studies of its inhibitors.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32006900","citation_count":41,"is_preprint":false},{"pmid":"25381821","id":"PMC_25381821","title":"Wip1 phosphatase in breast cancer.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25381821","citation_count":40,"is_preprint":false},{"pmid":"35025619","id":"PMC_35025619","title":"Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.","date":"2022","source":"JCO precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35025619","citation_count":40,"is_preprint":false},{"pmid":"37595362","id":"PMC_37595362","title":"PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37595362","citation_count":39,"is_preprint":false},{"pmid":"23907125","id":"PMC_23907125","title":"Genetic variants and mutations of PPM1D control the response to DNA damage.","date":"2013","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/23907125","citation_count":39,"is_preprint":false},{"pmid":"18333294","id":"PMC_18333294","title":"The Wip1 phosphatase and Mdm2: cracking the \"Wip\" on p53 stability.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18333294","citation_count":39,"is_preprint":false},{"pmid":"27183917","id":"PMC_27183917","title":"Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27183917","citation_count":38,"is_preprint":false},{"pmid":"26012568","id":"PMC_26012568","title":"Phosphatase Wip1 controls antigen-independent B-cell development in a p53-dependent manner.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26012568","citation_count":37,"is_preprint":false},{"pmid":"28417018","id":"PMC_28417018","title":"DNA damage-induced phosphatase Wip1 in regulation of hematopoiesis, immune system and inflammation.","date":"2017","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/28417018","citation_count":34,"is_preprint":false},{"pmid":"34131120","id":"PMC_34131120","title":"Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34131120","citation_count":32,"is_preprint":false},{"pmid":"23396447","id":"PMC_23396447","title":"DNA damage signaling induced by the G-quadruplex ligand 12459 is modulated by PPM1D/WIP1 phosphatase.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23396447","citation_count":32,"is_preprint":false},{"pmid":"18328948","id":"PMC_18328948","title":"PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.","date":"2008","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/18328948","citation_count":31,"is_preprint":false},{"pmid":"19395378","id":"PMC_19395378","title":"Loss of Wip1 sensitizes cells to stress- and DNA damage-induced apoptosis.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19395378","citation_count":29,"is_preprint":false},{"pmid":"22115592","id":"PMC_22115592","title":"A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.","date":"2011","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22115592","citation_count":29,"is_preprint":false},{"pmid":"23256545","id":"PMC_23256545","title":"Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis.","date":"2012","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/23256545","citation_count":29,"is_preprint":false},{"pmid":"25791630","id":"PMC_25791630","title":"Involvement of dysregulated Wip1 in manganese-induced p53 signaling and neuronal apoptosis.","date":"2015","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/25791630","citation_count":29,"is_preprint":false},{"pmid":"25659035","id":"PMC_25659035","title":"DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase.","date":"2015","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25659035","citation_count":28,"is_preprint":false},{"pmid":"36456590","id":"PMC_36456590","title":"PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36456590","citation_count":27,"is_preprint":false},{"pmid":"35773251","id":"PMC_35773251","title":"Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35773251","citation_count":27,"is_preprint":false},{"pmid":"26358280","id":"PMC_26358280","title":"Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.","date":"2015","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26358280","citation_count":27,"is_preprint":false},{"pmid":"25154814","id":"PMC_25154814","title":"Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.","date":"2014","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25154814","citation_count":27,"is_preprint":false},{"pmid":"32103600","id":"PMC_32103600","title":"Wip1 regulates Smad4 phosphorylation and inhibits TGF-β signaling.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32103600","citation_count":26,"is_preprint":false},{"pmid":"30852603","id":"PMC_30852603","title":"Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.","date":"2019","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30852603","citation_count":26,"is_preprint":false},{"pmid":"32294440","id":"PMC_32294440","title":"Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32294440","citation_count":26,"is_preprint":false},{"pmid":"31619012","id":"PMC_31619012","title":"WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31619012","citation_count":25,"is_preprint":false},{"pmid":"25823026","id":"PMC_25823026","title":"PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25823026","citation_count":25,"is_preprint":false},{"pmid":"28903382","id":"PMC_28903382","title":"MicroRNA16 regulates glioma cell proliferation, apoptosis and invasion by targeting Wip1-ATM-p53 feedback loop.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28903382","citation_count":25,"is_preprint":false},{"pmid":"37709843","id":"PMC_37709843","title":"Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.","date":"2023","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/37709843","citation_count":24,"is_preprint":false},{"pmid":"32229503","id":"PMC_32229503","title":"Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/32229503","citation_count":23,"is_preprint":false},{"pmid":"27077811","id":"PMC_27077811","title":"Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27077811","citation_count":23,"is_preprint":false},{"pmid":"25797250","id":"PMC_25797250","title":"WIP1 stimulates migration and invasion of salivary adenoid cystic carcinoma by inducing MMP-9 and VEGF-C.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25797250","citation_count":22,"is_preprint":false},{"pmid":"27086929","id":"PMC_27086929","title":"WIP1 modulates responsiveness to Sonic Hedgehog signaling in neuronal precursor cells and medulloblastoma.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27086929","citation_count":21,"is_preprint":false},{"pmid":"17977650","id":"PMC_17977650","title":"Identification of differentially expressed genes after PPM1D silencing in breast cancer.","date":"2007","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/17977650","citation_count":21,"is_preprint":false},{"pmid":"22379189","id":"PMC_22379189","title":"HDM2 promotes WIP1-mediated medulloblastoma growth.","date":"2012","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22379189","citation_count":20,"is_preprint":false},{"pmid":"31127650","id":"PMC_31127650","title":"Wip1 cooperates with KPNA2 to modulate the cell proliferation and migration of colorectal cancer via a p53-dependent manner.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31127650","citation_count":20,"is_preprint":false},{"pmid":"18991770","id":"PMC_18991770","title":"Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.","date":"2008","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/18991770","citation_count":20,"is_preprint":false},{"pmid":"25334029","id":"PMC_25334029","title":"Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25334029","citation_count":20,"is_preprint":false},{"pmid":"31659152","id":"PMC_31659152","title":"Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31659152","citation_count":19,"is_preprint":false},{"pmid":"34732238","id":"PMC_34732238","title":"TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.","date":"2021","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/34732238","citation_count":19,"is_preprint":false},{"pmid":"35657598","id":"PMC_35657598","title":"PPM1D in Solid and Hematologic Malignancies: Friend and Foe?","date":"2022","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/35657598","citation_count":18,"is_preprint":false},{"pmid":"26714478","id":"PMC_26714478","title":"PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.","date":"2016","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/26714478","citation_count":18,"is_preprint":false},{"pmid":"28915621","id":"PMC_28915621","title":"Wip1 is associated with tumorigenity and metastasis through MMP-2 in human intrahepatic cholangiocarcinoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28915621","citation_count":18,"is_preprint":false},{"pmid":"25601473","id":"PMC_25601473","title":"Wip1-deficient neutrophils significantly promote intestinal ischemia/reperfusion injury in mice.","date":"2015","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25601473","citation_count":18,"is_preprint":false},{"pmid":"37381752","id":"PMC_37381752","title":"Clonal hematopoiesis with DNMT3A and PPM1D mutations impairs regeneration in autologous stem cell transplant recipients.","date":"2023","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/37381752","citation_count":17,"is_preprint":false},{"pmid":"17219434","id":"PMC_17219434","title":"PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development.","date":"2007","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/17219434","citation_count":17,"is_preprint":false},{"pmid":"33616916","id":"PMC_33616916","title":"Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) mutations in haematological cancer.","date":"2020","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/33616916","citation_count":16,"is_preprint":false},{"pmid":"27401275","id":"PMC_27401275","title":"Truncating and missense PPM1D mutations in early-onset and/or familial/hereditary prostate cancer patients.","date":"2016","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27401275","citation_count":16,"is_preprint":false},{"pmid":"27619510","id":"PMC_27619510","title":"PPM1D controls nucleolar formation by up-regulating phosphorylation of nucleophosmin.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27619510","citation_count":16,"is_preprint":false},{"pmid":"28822916","id":"PMC_28822916","title":"Wip1-dependent modulation of macrophage migration and phagocytosis.","date":"2017","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/28822916","citation_count":16,"is_preprint":false},{"pmid":"33503543","id":"PMC_33503543","title":"p21WAF1/CIP1 promotes p53 protein degradation by facilitating p53-Wip1 and p53-Mdm2 interaction.","date":"2021","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/33503543","citation_count":16,"is_preprint":false},{"pmid":"33452162","id":"PMC_33452162","title":"Loss of Wip1 aggravates brain injury after ischaemia/reperfusion by overactivating microglia.","date":"2021","source":"Stroke and vascular neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33452162","citation_count":16,"is_preprint":false},{"pmid":"33309518","id":"PMC_33309518","title":"Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33309518","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47641,"output_tokens":8289,"usd":0.133629,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18033,"output_tokens":5870,"usd":0.118457,"stage2_stop_reason":"end_turn"},"total_usd":0.252086,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"PPM1D (Wip1) dephosphorylates and inactivates p38 MAPK, creating a negative feedback loop on p53 activity. Retrovirus-mediated overexpression of PPM1D reduced p53 phosphorylation at Ser33 and Ser46 (p38 MAPK target sites), abrogated Ras-induced apoptosis, and partially rescued cells from cell-cycle arrest.\",\n      \"method\": \"Retroviral overexpression, phosphorylation analysis, apoptosis/cell-cycle assays, MEF transformation assay in nude mice\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (overexpression, phosphorylation assays, in vivo tumor formation), replicated across subsequent studies\",\n      \"pmids\": [\"12021785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PPM1D binds Chk1 and dephosphorylates ATR-targeted phospho-Ser345, reducing Chk1 kinase activity. PPM1D also dephosphorylates p53 at phospho-Ser15. These dephosphorylations correlate with reduced intra-S and G2/M checkpoint activity after UV and ionizing radiation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, checkpoint activity assays after UV/IR\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical dephosphorylation assay with functional checkpoint readout, replicated in subsequent studies\",\n      \"pmids\": [\"15870257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Wip1 (PPM1D) dephosphorylates ATM at Ser1981, a site critical for ATM monomerization and activation, thereby resetting ATM phosphorylation as cells complete DNA repair. Overexpression of Wip1 reduces ATM-dependent signaling cascade activation after DNA damage; Wip1 deficiency results in constitutive ATM activation.\",\n      \"method\": \"In vitro phosphatase assay, overexpression and knockdown experiments, immunoblotting for ATM-S1981 phosphorylation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical dephosphorylation of ATM-S1981 demonstrated, replicated by multiple subsequent studies\",\n      \"pmids\": [\"16949371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PPM1D interacts with the nuclear isoform of uracil DNA glycosylase UNG2 and suppresses base excision repair (BER). PPM1D dephosphorylates UNG2 at phosphothreonine 6, reducing UNG2 activity. Point mutations inactivating PPM1D phosphatase activity abrogate BER suppression.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, active-site mutagenesis, BER activity assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in vitro with active-site mutagenesis, direct substrate identification with functional BER readout\",\n      \"pmids\": [\"15327777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Wip1 binds Chk2 and dephosphorylates phospho-Thr68 (the ATM-targeted activation site), thereby antagonizing Chk2 activation after ionizing irradiation. Wip1 overexpression suppresses the G2/M DNA damage checkpoint contribution of Chk2.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, G2/M checkpoint assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct biochemical dephosphorylation of Chk2-T68, functional checkpoint assay; independently confirmed by Yoda et al. same year\",\n      \"pmids\": [\"16936775\", \"16798742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Nuclear localization of both Chk2 and Wip1 is required for their association. The SQ/TQ domain of Chk2 (containing Thr68) and the N-terminal ~100 amino acids of Wip1 are necessary and sufficient for binding. Intrinsic kinase activity of Chk2 (but not phosphatase activity of Wip1) is required for their association when full-length proteins are used.\",\n      \"method\": \"Structure-function analysis with deletion and point mutants, co-immunoprecipitation, nuclear localization experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — systematic domain mapping with multiple mutants and Co-IP, functional rescue assays\",\n      \"pmids\": [\"16798742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Recombinant Wip1 catalytic domain dephosphorylates phosphoserine and phosphothreonine specifically in the p(S/T)Q motif (ATM/ATR substrate motif). Acidic, hydrophobic, or aromatic residues flanking the p(S/T)Q enhance dephosphorylation; basic residues have negative influence. New putative substrates identified include HDM2, SMC1A, ATR, and Wip1 itself.\",\n      \"method\": \"In vitro phosphatase kinetics with peptide variants, site-directed mutagenesis, 3D molecular modeling\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — detailed kinetic analysis of recombinant enzyme with substrate peptide variants and mutagenesis\",\n      \"pmids\": [\"17939684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PPM1D (Wip1) dephosphorylates Mdm2 at Ser395 (an ATM target site), stabilizing Mdm2, enhancing Mdm2-p53 binding, and promoting ubiquitination and degradation of p53. Wip1 thus facilitates Mdm2-mediated p53 degradation as part of a negative feedback loop.\",\n      \"method\": \"In vitro phosphatase assay, co-immunoprecipitation, ubiquitination assay, p53 stability measurements\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical dephosphorylation and functional p53 degradation assays, single lab\",\n      \"pmids\": [\"18333294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Wip1 directly dephosphorylates γ-H2AX (phospho-H2AX) in vitro and in vivo. Ectopic Wip1 expression significantly reduces γ-H2AX levels after ionizing radiation and UV; forced premature dephosphorylation disrupts recruitment of DNA repair factors to damage sites and delays DNA damage repair.\",\n      \"method\": \"In vitro phosphatase assay, ectopic expression, immunofluorescence, DNA repair kinetics assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct in vitro dephosphorylation plus in vivo functional consequences on repair factor recruitment\",\n      \"pmids\": [\"20460517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"WIP1 overexpression inhibits nucleotide excision repair (NER) kinetics in a phosphatase-activity-dependent manner; phosphatase-dead WIP1 mutants fail to inhibit NER. XPA and XPC are identified as potential WIP1 dephosphorylation targets in the NER pathway.\",\n      \"method\": \"Overexpression and depletion experiments, CPD repair kinetics assay, in vitro phosphatase assay with XPA/XPC, phosphatase-dead mutant analysis\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — phosphatase-dead mutant controls establish catalytic requirement; in vitro substrate identification; Wip1 null mice corroborate findings\",\n      \"pmids\": [\"20451471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Truncating gain-of-function mutations in exon 6 of PPM1D (carboxy-terminal to the phosphatase domain) result in enhanced suppression of p53 in response to ionizing radiation, without simple loss of function. These mosaic mutations encode hyperactive PPM1D isoforms.\",\n      \"method\": \"Next-generation sequencing, functional p53 suppression assay after IR in cells with exon 6 truncating variants\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional validation in cells, single lab but large case-control dataset\",\n      \"pmids\": [\"23242139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Exon 6 truncating mutations in PPM1D result in C-terminally truncated Wip1 with gain-of-function activity that impairs the p53-dependent G1 checkpoint and affects the DNA damage response pathway.\",\n      \"method\": \"Identification and functional characterization of exon 6 mutations, cell cycle checkpoint assay, DDR pathway analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional checkpoint assays with defined mutants, single lab\",\n      \"pmids\": [\"23649806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Wip1 is required for epigenetic remodeling of heterochromatin through regulation of BRCA1 interaction with HP1, recruitment of DNA methyltransferases, and subsequent DNA methylation. ATM attenuation reverses heterochromatin methylation, placing Wip1 upstream of ATM in heterochromatin silencing.\",\n      \"method\": \"Chromatin immunoprecipitation, DNA methylation assays, co-immunoprecipitation (BRCA1-HP1), genetic epistasis with ATM\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple ChIP and co-IP approaches, genetic epistasis, single lab\",\n      \"pmids\": [\"24135283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PPM1D exon 6 truncating mutations in brainstem gliomas enhance PPM1D's ability to suppress CHK2 activation and attenuate p53 activation in vitro, establishing these as gain-of-function somatic driver mutations.\",\n      \"method\": \"Exome sequencing, functional in vitro assays for CHK2 suppression and p53 activation\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional validation of identified mutations, single study\",\n      \"pmids\": [\"24880341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Allosteric small-molecule inhibitors of Wip1 bind a 'flap' subdomain near the catalytic site that is structurally divergent from other PP2C family members, conferring selectivity. GSK2830371 binding to this site increases phosphorylation of Wip1 substrates and inhibits growth of hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53.\",\n      \"method\": \"Structure-activity relationship, biochemical binding assay, pharmacodynamic studies, xenograft tumor model\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — structural basis of inhibition defined, multiple orthogonal biochemical and cellular methods, in vivo validation\",\n      \"pmids\": [\"24390428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Phosphoglycerate mutase 1 (PGAM1) binds WIP1 in the cytoplasm, preventing its nuclear translocation and subsequent dephosphorylation of the ATM signaling pathway, thereby regulating DNA damage response efficiency.\",\n      \"method\": \"Co-immunoprecipitation (cytoplasmic fractionation), PGAM1 knockdown, γ-H2AX foci assay, kinase-dead mutant rescue\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with subcellular fractionation, functional DDR readout, non-enzymatic PGAM1 mutant rescue establishes mechanism\",\n      \"pmids\": [\"32294440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PPM1D interacts with and dephosphorylates Ulk1 at Ser637 in a p53-dependent manner after genotoxic stress, triggering Ulk1 puncta formation and inducing autophagy. Genetic ablation of PPM1D reduces Ulk1 Ser637 dephosphorylation, inhibits autophagy, and accelerates apoptosis induced by X-ray irradiation by preventing autophagic degradation of proapoptotic Noxa.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, Ulk1 puncta imaging, genetic KO, autophagy flux assay, apoptosis assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct biochemical interaction and dephosphorylation established, genetic KO corroborates physiological role with specific molecular readouts\",\n      \"pmids\": [\"27670885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PPM1D dephosphorylates RBM38 at serine 195, modulating p53 mRNA translation. RBM38 directly binds PPM1D 3'-UTR and promotes PPM1D expression; PPM1D dephosphorylation of RBM38 reduces p53 mRNA translation and p53-dependent growth suppression.\",\n      \"method\": \"Co-immunoprecipitation, in vitro dephosphorylation assay, luciferase reporter (3'-UTR), RNA-binding assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct biochemical dephosphorylation and RNA-binding assays demonstrated, single lab\",\n      \"pmids\": [\"25823026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Wip1 deficiency in HSCs leads to sustained p53 activation, impaired repopulating activity, and aging-like phenotypes. Deletion of p53 (but not p21) completely rescues the multilineage repopulation defect of Wip1-deficient HSCs, defining a Wip1-p53 axis in HSC differentiation. Separately, HSC pool expansion in Wip1-/- mice is mediated by mTORC1-dependent proliferation, distinct from the p53-dependent differentiation defect.\",\n      \"method\": \"Conditional knockout, bone marrow transplantation competition assay, genetic epistasis (p53 deletion rescue), flow cytometry, mTORC1 pathway analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with rescue experiment separates two distinct pathways; multiple orthogonal in vivo methods\",\n      \"pmids\": [\"25879755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PPM1D truncating mutations (exon 6) encode a protein with elevated expression and activity due to loss of a C-terminal degradation domain. Global phosphoproteomic profiling in PPM1D-mutant cells reveals altered phosphorylation of DNA damage response targets. PPM1D-mutant cells show abrogated DDR, altered cell cycle progression, decreased apoptosis, and reduced mitochondrial priming in the presence of chemotherapy.\",\n      \"method\": \"Phosphoproteomics (mass spectrometry), CRISPR mutational profiling, cell cycle and apoptosis assays, mitochondrial priming assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — global phosphoproteomics plus multiple orthogonal functional assays, CRISPR validation\",\n      \"pmids\": [\"29954749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"WIP1 promotes homologous recombination (HR) DNA repair. WIP1 interacts with BRCA1 and dephosphorylates it; WIP1 activity is needed for correct dynamics of BRCA1 recruitment to chromatin flanking DNA lesions. WIP1 also dephosphorylates 53BP1 at Threonine 543, previously implicated in mediating interaction with RIF1. Loss/inhibition of WIP1 delayed disappearance of IR-induced 53BP1 foci in S/G2 cells and increased sensitivity to PARP inhibitor olaparib.\",\n      \"method\": \"Co-immunoprecipitation, in vitro dephosphorylation assay, immunofluorescence (53BP1/BRCA1 foci), WIP1 inhibitor treatment, olaparib sensitivity assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding and biochemical dephosphorylation of BRCA1 and 53BP1 demonstrated, functional HR readout, single lab\",\n      \"pmids\": [\"31619012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Mutant PPM1D drives CpG island hypermethylation genome-wide and promotes epigenetic silencing of NAPRT (a NAD biosynthesis gene), creating a synthetic lethal interaction with NAMPT inhibitors.\",\n      \"method\": \"Isogenic cell lines, genome-wide methylation profiling, NAMPT inhibitor sensitivity assay in vitro and in vivo\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isogenic models with mechanistic methylation data and in vivo validation, single lab\",\n      \"pmids\": [\"31439867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Wip1 selectively binds and dephosphorylates Smad4 at Thr277 (a key MAPK phosphorylation site in the linker region), regulating Smad4 nuclear accumulation and half-life. This inhibits TGF-β/BMP signaling; in Xenopus embryos, Wip1 limits mesoderm formation by inhibiting TGF-β/BMP signals.\",\n      \"method\": \"Co-immunoprecipitation, in vitro phosphatase assay, nuclear fractionation, Xenopus embryo gain/loss-of-function, cell migration/invasion assay\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct biochemical binding and dephosphorylation, functional in vivo Xenopus model, subcellular localization consequences defined\",\n      \"pmids\": [\"32103600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PPM1D regulates nucleolar formation by controlling phosphorylation of nucleophosmin (NPM). PPM1D overexpression induces increased nucleolar number independently of p53 status. PPM1D acts as an upstream regulator in a PPM1D-CDC25C-CDK1-PLK1 signaling pathway that controls sequential NPM phosphorylation required for nucleolar formation.\",\n      \"method\": \"Overexpression, knockdown, immunofluorescence (nucleolar counting), phospho-NPM analysis, pathway epistasis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional pathway placement with mechanistic cascade delineation, single lab, p53-independence established\",\n      \"pmids\": [\"27619510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GSK2830371 binds an allosteric site of PPM1D (the flap domain). Hydrogen-deuterium exchange mass spectrometry and analytical ultracentrifugation reveal PPM1D exists in equilibrium between two conformations defined by flap domain movement; GSK2830371 shifts the equilibrium to the inactive (flap-closed) form. C-terminal truncating mutations proximal to residue 400 destabilize the protein via loss of a stabilizing N- and C-terminal interaction.\",\n      \"method\": \"HDX-MS, sedimentation velocity analytical ultracentrifugation, computational modeling, biochemical binding assays, functional genetic studies\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple structural/biophysical methods (HDX-MS, AUC) plus biochemical and functional genetic validation in a single rigorous study\",\n      \"pmids\": [\"35773251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PPM1D inhibition induces phosphorylation of eIF2α and ATF4 accumulation, linking PPM1D to the integrated stress response (ISR). PPM1D inhibition depletes heme and induces HRI-dependent eIF2α phosphorylation. Dual inhibition of PPM1D and MDM2 synergistically induces apoptosis via amplification of p53 transcriptional program through the eIF2α-ATF4 pathway.\",\n      \"method\": \"PPM1D inhibitor treatment, eIF2α phosphorylation assay, ATF4 reporter, HRI pathway analysis, RNA-seq, in vivo tumor growth assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway dissection with pharmacological and genetic tools, in vivo validation, single lab\",\n      \"pmids\": [\"36456590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A conserved p53 response element in the 5' UTR of the PPM1D gene is required for p53-dependent transcriptional induction after genotoxic stress. CREB binding to a CRE element in the promoter regulates basal PPM1D expression. After UV/IR exposure, increased PPM1D protein levels can occur without increased mRNA, indicating post-transcriptional regulation.\",\n      \"method\": \"Transient transfection, chromatin immunoprecipitation, promoter reporter assay, mRNA/protein comparison after DNA damage\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assays establish transcriptional mechanism, single lab, multiple methods\",\n      \"pmids\": [\"19015127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Wip1 deficiency prevents fat accumulation and atherosclerosis in mice. During atherosclerosis, Wip1 deletion suppresses macrophage conversion to foam cells by acting via a non-canonical ATM-mTOR signaling pathway and selective autophagy to regulate cholesterol efflux, in a p53-independent manner.\",\n      \"method\": \"Wip1 knockout mouse model, atherosclerosis model, macrophage foam cell assay, autophagy and cholesterol efflux assays, genetic epistasis with ATM/mTOR\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with mechanistic dissection of ATM-mTOR-autophagy pathway, p53-independence established, single lab\",\n      \"pmids\": [\"22768840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"WIP1 promotes medulloblastoma cell growth and invasion through regulation of CXCR4 cell surface localization via suppression of GRK5 expression. GRK5 promotes Ser339 phosphorylation of CXCR4 and inhibits cell surface CXCR4; WIP1 knockdown reduces GRK5-dependent CXCR4 phosphorylation, decreasing surface CXCR4 and invasion.\",\n      \"method\": \"Stable knockdown/overexpression, xenograft mouse model, cell surface CXCR4 assay, GRK5 manipulation, invasion assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo mechanistic pathway delineation, multiple molecular manipulations, single lab\",\n      \"pmids\": [\"24632620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"WIP1 regulates adult neurogenesis by controlling DKK3-dependent inhibition of WNT signaling. WIP1 is expressed in neural stem/progenitor cells (NPCs) of the mouse SVZ; WIP1 suppresses expression of the WNT pathway inhibitor DKK3. DKK3 inhibits neuroblast formation by suppressing WNT signaling, and Wip1-dependent control of DKK3 promotes neuronal differentiation.\",\n      \"method\": \"Transgenic mice with enhanced WIP1 expression, Dkk3 deletion, pharmacological WNT activation, SVZ reporter strain, olfactory behavioral testing\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (Wip1 → DKK3 → WNT) established with multiple mouse models and functional behavioral readout\",\n      \"pmids\": [\"24911145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Loss of Wip1 sensitizes mouse embryonic fibroblasts to stress-induced apoptosis via activation of both p38-ATF2 and JNK-c-Jun signaling. Wip1 negatively regulates MKK4-JNK-c-Jun signaling during stress-induced apoptosis, representing a dual role in regulating both p38/p53-dependent and JNK-dependent apoptotic pathways.\",\n      \"method\": \"Wip1 knockout MEFs, stress-induced apoptosis assays, kinase activity measurements (p38, JNK), phospho-ATF2/c-Jun analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with pathway dissection, single lab, multiple kinase pathway readouts\",\n      \"pmids\": [\"19395378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"p21WAF1/CIP1 promotes the interaction between p53 and Wip1 by forming a trimeric complex (p53-p21-Wip1), facilitating Wip1-mediated dephosphorylation of p53-S15 and subsequent Mdm2-mediated p53 degradation. A p21 deletion mutant unable to bind p53 cannot facilitate p53-Wip1 interaction.\",\n      \"method\": \"Co-immunoprecipitation, deletion mutant analysis, p53 stability assay, phospho-S15 immunoblotting\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with domain mapping establishes trimeric complex, functional phosphorylation readout, single lab\",\n      \"pmids\": [\"33503543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Wip1-deficient macrophages show enhanced migration mediated by Rac1-GTPase and PI3K/AKT signaling pathways. Enhanced phagocytic ability of Wip1-/- macrophages is linked to CD36 plasma membrane recruitment regulated by AMPK activity.\",\n      \"method\": \"Wip1 knockout macrophage migration and phagocytosis assays, Rac1-GTPase activity measurement, PI3K/AKT pathway analysis, AMPK activity, CD36 membrane recruitment assay\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with mechanistic pathway dissection, multiple signaling pathway measurements, single lab\",\n      \"pmids\": [\"28822916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Akt stabilizes PPM1D protein by inhibiting CDDP-induced proteasomal degradation. In chemoresistant gynecological cancer cells, CDDP induces PPM1D nuclear localization while sensitive cells show nuclear exclusion. Active Akt overexpression in sensitive cells stabilizes PPM1D and prevents degradation.\",\n      \"method\": \"Nuclear/cytoplasmic fractionation, proteasome inhibitor assay, Akt overexpression/inhibition, PPM1D stability measurements\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular localization determined by fractionation with functional consequence, Akt regulation of PPM1D stability established, single lab\",\n      \"pmids\": [\"25154814\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PPM1D (Wip1) is a p53-inducible PP2C-family serine/threonine phosphatase that dephosphorylates and inactivates multiple ATM/ATR pathway substrates—including ATM-pS1981, Chk1-pS345, Chk2-pT68, p53-pS15, γ-H2AX, Mdm2-pS395, Ulk1-pS637, Smad4-pT277, BRCA1, 53BP1-pT543, UNG2-pT6, RBM38-pS195, XPA, and XPC—thereby acting as a homeostatic phosphatase that attenuates the DNA damage response, cell cycle checkpoints, base excision repair, nucleotide excision repair, and homologous recombination after DNA repair is complete; its oncogenic amplification or C-terminal truncating gain-of-function mutations increase protein stability and phosphatase activity, broadly suppressing tumor suppressor pathways including p53, p38 MAPK, and ATM, while allosteric inhibitors such as GSK2830371 lock the flap subdomain in an inactive conformation to restore these pathways in cancer cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PPM1D (Wip1) is a p53-inducible PP2C-family serine/threonine phosphatase that acts as a homeostatic brake on the DNA damage response, dephosphorylating ATM/ATR pathway substrates within the p(S/T)Q motif to reset checkpoint signaling once repair is complete [#1, #6]. Its catalytic domain recognizes phospho-Ser/Thr in p(S/T)Q sequences, with flanking acidic/hydrophobic residues enhancing turnover [#6], and it directly inactivates the core checkpoint machinery: ATM at Ser1981 [#2], Chk1 at Ser345 [#1], Chk2 at Thr68 [#4, #5], p53 at Ser15 [#1], and \\u03b3-H2AX [#8]. PPM1D reinforces a negative feedback loop on p53 both by dephosphorylating Mdm2-Ser395 to promote Mdm2-mediated p53 degradation [#7]\\u2014a process facilitated by a p53-p21-Wip1 trimeric complex [#31]\\u2014and by inactivating p38 MAPK to attenuate p53 phosphorylation and apoptosis [#0]. Its own induction is driven by a p53 response element in the 5'UTR after genotoxic stress [#26]. Beyond canonical checkpoint control, PPM1D suppresses multiple repair pathways by dephosphorylating UNG2-Thr6 (base excision repair) [#3], XPA/XPC (nucleotide excision repair) [#9], and BRCA1 and 53BP1-Thr543 (homologous recombination) [#20], and it extends to autophagy via Ulk1-Ser637 [#16], TGF-\\u03b2/BMP signaling via Smad4-Thr277 [#22], and p53 mRNA translation via RBM38-Ser195 [#17]. Oncogenic activation occurs through amplification or C-terminal exon 6 truncating gain-of-function mutations that remove a degradation domain, elevating protein stability and activity and broadly suppressing p53 and DDR signaling [#10, #11, #19, #24]. The allosteric inhibitor GSK2830371 binds a divergent 'flap' subdomain and shifts PPM1D toward an inactive flap-closed conformation, restoring substrate phosphorylation and selectively impairing growth of Wip1-amplified, TP53-wild-type tumors [#14, #24]. PPM1D also has p53-independent physiological roles in hematopoietic stem cell homeostasis, neurogenesis, macrophage function, and atherosclerosis [#18, #27, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established PPM1D as a phosphatase that closes a negative feedback loop on stress signaling, dephosphorylating p38 MAPK to limit p53 activation and apoptosis\\u2014defining its oncogenic potential.\",\n      \"evidence\": \"Retroviral overexpression with phosphorylation, apoptosis, and in vivo MEF transformation assays\",\n      \"pmids\": [\"12021785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify direct DDR kinase substrates\", \"p38 dephosphorylation may be indirect\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Extended PPM1D's reach beyond checkpoints to DNA repair itself by showing direct dephosphorylation of UNG2-Thr6 suppresses base excision repair.\",\n      \"evidence\": \"Co-IP, in vitro phosphatase assay with active-site mutants, BER activity readout\",\n      \"pmids\": [\"15327777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of BER suppression not established\", \"Did not place UNG2 regulation in broader repair context\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified PPM1D as a direct antagonist of the ATR-Chk1 and p53 checkpoint arms, dephosphorylating Chk1-Ser345 and p53-Ser15 to dampen intra-S and G2/M checkpoints.\",\n      \"evidence\": \"Co-IP, in vitro phosphatase assays, checkpoint readouts after UV/IR\",\n      \"pmids\": [\"15870257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address upstream ATM/ATR directly\", \"Relative contribution of each substrate to checkpoint output unquantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed PPM1D at the apex of DDR reset by demonstrating it dephosphorylates ATM-Ser1981 and Chk2-Thr68, defining nuclear localization and N-terminal/SQ-TQ domain requirements for substrate binding.\",\n      \"evidence\": \"In vitro phosphatase assays, knockdown/overexpression, structure-function domain mapping\",\n      \"pmids\": [\"16949371\", \"16936775\", \"16798742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics of ATM reset relative to repair completion not resolved\", \"Whether ATM dephosphorylation is direct or scaffold-dependent in cells\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the biochemical substrate logic of PPM1D as a p(S/T)Q-directed phosphatase, rationalizing its selectivity for ATM/ATR substrates and predicting new targets.\",\n      \"evidence\": \"In vitro phosphatase kinetics with peptide variants, mutagenesis, molecular modeling\",\n      \"pmids\": [\"17939684\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Predicted substrates (HDM2, SMC1A, ATR) not all validated in cells\", \"No experimental structure of substrate-bound enzyme\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected PPM1D to p53 turnover and its own transcriptional induction, showing Mdm2-Ser395 dephosphorylation promotes p53 degradation and a p53 response element drives PPM1D expression.\",\n      \"evidence\": \"In vitro phosphatase, ubiquitination, p53 stability assays; ChIP and promoter reporters\",\n      \"pmids\": [\"18333294\", \"19015127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Post-transcriptional induction mechanism after UV/IR undefined\", \"Mdm2 stabilization mechanism single-lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed PPM1D directly dephosphorylates \\u03b3-H2AX and suppresses nucleotide excision repair, establishing premature dephosphorylation as a means of disrupting repair-factor recruitment.\",\n      \"evidence\": \"In vitro phosphatase assays, ectopic expression, immunofluorescence, repair kinetics with phosphatase-dead controls\",\n      \"pmids\": [\"20460517\", \"20451471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"XPA/XPC identified as potential rather than confirmed in vivo substrates\", \"Timing of \\u03b3-H2AX reset versus repair completion not fully resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Reframed PPM1D mutation from loss to gain of function, showing exon 6 truncating mutations encode hyperactive isoforms that enhance p53 suppression after irradiation.\",\n      \"evidence\": \"NGS plus functional p53 suppression assays in cells carrying exon 6 variants\",\n      \"pmids\": [\"23242139\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of hyperactivity not yet defined at this stage\", \"Clonal context of mosaic mutations unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined exon 6 truncating mutations as G1-checkpoint-impairing gain-of-function alleles and linked PPM1D to BRCA1/HP1-dependent heterochromatin silencing upstream of ATM.\",\n      \"evidence\": \"Mutant functional checkpoint assays; ChIP, DNA methylation, co-IP, and ATM epistasis\",\n      \"pmids\": [\"23649806\", \"24135283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Heterochromatin role single-lab and mechanism of DNMT recruitment incomplete\", \"Direct vs indirect BRCA1 effect on methylation unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified the druggable allosteric flap subdomain and validated PPM1D as a selective therapeutic target, while expanding its oncogenic roles to brainstem glioma drivers, CXCR4/GRK5 invasion, and WNT-dependent neurogenesis.\",\n      \"evidence\": \"SAR and GSK2830371 binding/PD/xenograft studies; exome sequencing with functional CHK2/p53 assays; knockdown/xenograft invasion and neurogenesis mouse models\",\n      \"pmids\": [\"24390428\", \"24880341\", \"24632620\", \"24911145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Detailed conformational mechanism of inhibition not yet defined at this stage\", \"Tissue specificity of CXCR4 and WNT roles unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Broadened PPM1D's substrate repertoire to autophagy (Ulk1-Ser637), p53 mRNA translation (RBM38-Ser195), HR repair via BRCA1, and revealed a p53-dependent HSC differentiation axis distinct from mTORC1-driven HSC expansion.\",\n      \"evidence\": \"Co-IP, in vitro dephosphorylation, autophagy flux/apoptosis assays, RNA-binding/luciferase, conditional KO with p53-deletion rescue and transplantation\",\n      \"pmids\": [\"27670885\", \"25823026\", \"25879755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RBM38 feedback loop single-lab\", \"Tissue-specific balance of these substrates unquantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a p53-independent role in nucleolar biogenesis through a PPM1D-CDC25C-CDK1-PLK1 cascade controlling NPM phosphorylation.\",\n      \"evidence\": \"Overexpression/knockdown, nucleolar counting, phospho-NPM analysis, pathway epistasis\",\n      \"pmids\": [\"27619510\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect control of NPM phosphorylation unclear\", \"Single-lab pathway placement\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined p53-independent immune functions: Wip1 loss enhances macrophage migration via Rac1-PI3K/AKT and phagocytosis via AMPK-driven CD36 recruitment.\",\n      \"evidence\": \"Wip1 KO macrophage migration/phagocytosis assays with Rac1, PI3K/AKT, AMPK pathway readouts\",\n      \"pmids\": [\"28822916\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrates in these pathways not identified\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided the mechanistic basis for gain-of-function mutations\\u2014loss of a C-terminal degradation domain elevating PPM1D abundance and activity\\u2014and globally mapped the resulting DDR phosphoproteome changes.\",\n      \"evidence\": \"Phosphoproteomics, CRISPR mutational profiling, cell cycle/apoptosis and mitochondrial priming assays\",\n      \"pmids\": [\"29954749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which phosphoproteomic changes are direct substrates unresolved\", \"Chemoresistance mechanism only partially mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established PPM1D as a regulator of HR repair through BRCA1 and 53BP1-Thr543 dephosphorylation and revealed a therapeutically exploitable epigenetic vulnerability (NAPRT silencing, NAMPT synthetic lethality) in mutant cells.\",\n      \"evidence\": \"Co-IP, in vitro dephosphorylation, 53BP1/BRCA1 foci imaging, olaparib sensitivity; isogenic lines with genome-wide methylation and NAMPT inhibitor assays\",\n      \"pmids\": [\"31619012\", \"31439867\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HR role single-lab\", \"Mechanism linking mutant PPM1D to CpG hypermethylation incomplete\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended PPM1D into developmental signaling control by showing Smad4-Thr277 dephosphorylation limits TGF-\\u03b2/BMP signaling and mesoderm formation, and identified PGAM1 as a cytoplasmic sequestering regulator of PPM1D nuclear import.\",\n      \"evidence\": \"Co-IP, in vitro phosphatase, nuclear fractionation, Xenopus gain/loss-of-function; cytoplasmic co-IP with non-enzymatic PGAM1 mutant rescue\",\n      \"pmids\": [\"32103600\", \"32294440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contexts of Smad4 regulation in mammals unclear\", \"Signals controlling PGAM1-PPM1D binding undefined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined the conformational mechanism of allosteric inhibition\\u2014GSK2830371 locks a flap-domain equilibrium in the inactive state\\u2014and linked PPM1D inhibition to the integrated stress response, enabling MDM2-combination apoptosis.\",\n      \"evidence\": \"HDX-MS, analytical ultracentrifugation, modeling, biochemistry; eIF2\\u03b1/ATF4/HRI pathway analysis, RNA-seq, in vivo tumor assays\",\n      \"pmids\": [\"35773251\", \"36456590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution crystal/cryo-EM structure of inhibitor-bound PPM1D\", \"ISR linkage to heme depletion mechanism single-lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PPM1D's broad substrate set is spatiotemporally prioritized\\u2014and which downstream effects of gain-of-function mutants are direct catalytic events versus secondary consequences\\u2014remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental structure of substrate- or full-length protein\", \"Substrate prioritization across DDR, autophagy, translation, and developmental signaling not integrated\", \"Direct vs indirect basis of mutant-driven epigenetic and metabolic phenotypes\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 3, 4, 6, 7, 8, 16, 17, 20, 22]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 6, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 15, 33]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [2, 3, 8, 9, 20]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 4, 11, 23]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 2, 25, 30]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [16, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 22, 28, 29, 32]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [12, 21]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 16, 30]}\n    ],\n    \"complexes\": [\"p53-p21-Wip1 trimeric complex\"],\n    \"partners\": [\"TP53\", \"CHEK1\", \"CHEK2\", \"ATM\", \"MDM2\", \"BRCA1\", \"UNG\", \"PGAM1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}